Highlights
- A 2026 Blood study identifies a bone marrow macrophage subset marked by CD64, CD169, CD163, CSF-1R, PD-L1, and CD155 that is enriched in patients who relapse after autologous stem cell transplantation (ASCT) for multiple myeloma.
- In a preclinical ASCT model, neither lenalidomide nor CSF-1R inhibition alone substantially improved disease control, but the combination significantly delayed progression and prolonged survival.
- Single-cell analyses suggest a mechanistic explanation: lenalidomide expands NK-like CD8 T-cell states while simultaneously increasing suppressive Csf1r+ macrophages; CSF-1R blockade removes this macrophage brake and restores T-cell activation.
- The work reframes post-ASCT relapse as a problem not only of residual tumor burden, but also of a therapy-shaped marrow immune niche, thereby nominating CSF-1R-targeted maintenance combinations as a clinically testable strategy.
Background
Multiple myeloma remains a largely incurable plasma-cell malignancy despite major therapeutic advances. For transplant-eligible patients, induction therapy followed by high-dose melphalan and ASCT remains a core component of frontline management, particularly because it deepens response and prolongs progression-free survival (PFS). Since the 2010s, maintenance lenalidomide has become the dominant post-ASCT standard after randomized trials demonstrated meaningful PFS benefit and, in pooled analyses, an overall survival advantage. Yet relapse after ASCT remains common, even among patients who achieve deep remissions.
This gap has focused attention on measurable residual disease, clonal evolution, and increasingly, the marrow immune microenvironment. Myeloma is highly dependent on reciprocal interactions with stromal, myeloid, and lymphoid compartments. Tumor-associated macrophages (TAMs), myeloid-derived suppressor cells, dysfunctional dendritic cells, and exhausted T cells all contribute to immune escape. However, the post-transplant setting is biologically distinctive: marrow injury, immune reconstitution, cytokine flux, and maintenance therapy together may create a selective niche in which residual myeloma either remains controlled or re-expands.
The study by Minnie and colleagues adds an important translational layer to this problem. Rather than examining myeloid suppression in advanced relapsed disease alone, the investigators asked whether specific bone marrow macrophage states correlate with failure of ASCT and whether those states are therapeutically actionable. Their answer is clinically provocative: a CSF-1R-expressing suppressive macrophage population appears linked to relapse, and targeting this axis may unlock the full immunologic potential of lenalidomide maintenance.
Key Content
Established evidence: ASCT and lenalidomide maintenance remain the benchmark
The starting point for interpreting the 2026 study is the robust evidence base supporting lenalidomide maintenance after ASCT. Two pivotal randomized trials published in 2012 firmly established the strategy. In CALGB 100104, McCarthy and colleagues showed that continuous lenalidomide maintenance after ASCT significantly prolonged time to progression and improved overall survival compared with placebo. In the IFM 2005-02 trial, Attal and colleagues likewise demonstrated prolonged PFS with lenalidomide maintenance, although the overall survival signal was less immediate and concerns emerged regarding second primary malignancies. These concerns persisted, but the therapeutic index remained favorable because myeloma control improved substantially.
The most influential integrative analysis came from the meta-analysis by Holstein et al., which pooled patient-level data from three randomized studies and confirmed significant improvement in both PFS and overall survival with post-ASCT lenalidomide maintenance. That analysis cemented lenalidomide as the maintenance reference standard for transplant-eligible patients not proceeding to alternative strategies such as tandem transplantation or newer trial-based consolidation platforms.
Still, the limits of lenalidomide maintenance are equally important. It delays relapse more effectively than it prevents relapse. Patients with high-risk cytogenetics, persistent residual disease, or adverse marrow immune signatures remain vulnerable. This clinical reality makes the Minnie et al. report especially relevant: the unmet need is not whether maintenance matters, but how to make maintenance immunologically more effective.
The biological rationale: myeloma persistence is sustained by the marrow myeloid niche
Myeloma is a canonical microenvironment-driven malignancy. The marrow niche promotes plasma-cell survival through IL-6, BAFF, APRIL, CXCL12, integrin-mediated adhesion, angiogenic signaling, and direct immunosuppressive cross-talk. Among immune populations, macrophages have emerged as versatile contributors to disease biology. They can protect myeloma cells from drug-induced apoptosis, support angiogenesis, and dampen cytotoxic lymphocyte function.
CSF-1R is a particularly attractive node in this network. Expressed largely on monocytes and macrophages, it regulates differentiation, survival, and tissue accumulation of myeloid cells in response to colony-stimulating factor 1 and IL-34. In solid tumors, CSF-1/CSF-1R signaling has long been recognized as a driver of macrophage recruitment and immunosuppressive polarization, and several CSF-1R-targeting agents have entered clinical development. Translating this concept to myeloma has been plausible, but the field lacked a compelling post-ASCT disease model showing why and when such targeting would matter.
Minnie et al. fill that gap by identifying a clinically relevant macrophage phenotype expanded in patients relapsing after ASCT. The cells expressed CD64, CD169, and CD163 along with CSF-1R, PD-L1, and CD155, implying a mature, immunoregulatory macrophage state capable of suppressing antitumor lymphocytes through multiple checkpoint-like interactions. The combination of PD-L1 and CD155 is especially notable because it links myeloid suppression to both canonical PD-1 signaling and DNAM-1/TIGIT/CD96 pathway biology.
The 2026 Blood study: major findings and translational significance
The principal contribution of Minnie et al. is not merely descriptive immunophenotyping, but mechanistically anchored therapeutic testing. The investigators first associated expansion of CSF-1R-positive suppressive macrophages with relapse after ASCT in patient samples. They then modeled the post-transplant state in a preclinical myeloma ASCT platform with intentionally suboptimal endogenous antimyeloma activity. This is an important design feature because it reflects the clinically common circumstance in which transplant and maintenance suppress disease without fully eradicating residual malignant clones.
In that model, neither lenalidomide alone nor CSF-1R inhibition alone substantially improved outcomes. The negative monotherapy result strengthens the study because it argues against simple additive antitumor effects. By contrast, the combination significantly attenuated disease progression and prolonged survival, supporting true biologic synergy.
Single-cell RNA sequencing provided the mechanistic framework. Lenalidomide expanded NK-like CD8 T cells, a finding consistent with the known immunomodulatory properties of cereblon-binding IMiDs, including enhancement of T-cell and natural killer-cell activation. However, lenalidomide also paradoxically increased Csf1r+ macrophages, suggesting that its net immunologic output may be constrained by compensatory myeloid suppression. Cell-cell communication analyses then positioned these macrophages as inhibitors of two key effector populations: NK-like CD8 T cells and effector-like phenotypically exhausted CD8 T cells (Tphex). The inferred suppressive interactions involved CD94/NKG2A and PD-L1/PD-1 axes, respectively. When CSF-1R signaling was blocked, the suppressive macrophage compartment contracted, inhibitory receptor expression fell, and activation markers increased in Tphex cells.
The translational implication is crisp: lenalidomide may generate or expand potentially useful cytotoxic lymphocyte states after ASCT, but concomitant accumulation of CSF-1R+ macrophages blunts this benefit. Removing the macrophage brake converts a modest immunologic effect into clinically meaningful disease control in the model.
How this study fits with prior knowledge of lenalidomide immunobiology
Lenalidomide has always been more than a direct antimyeloma agent. Through cereblon-mediated degradation of Ikaros and Aiolos, it promotes IL-2 production, enhances T-cell and NK-cell activation, and modulates cytokine networks. These effects help explain why lenalidomide is effective both as part of induction combinations and as maintenance. Yet the post-ASCT setting has exposed the limits of this mechanism: immune reconstitution after high-dose melphalan is incomplete, functionally heterogeneous, and vulnerable to suppressive repolarization within the marrow.
The Minnie et al. data suggest that lenalidomide’s immune effects are context dependent. In a permissive microenvironment, expansion of activated or NK-like cytotoxic lymphocytes may translate into sustained tumor control. In a suppressive marrow enriched for CSF-1R+ macrophages expressing PD-L1 and CD155, those same lymphocytes may be rendered dysfunctional. This observation also helps reconcile why lenalidomide maintenance improves outcomes on average yet does not fully overcome relapse risk in biologically adverse patients.
From a translational standpoint, this means future maintenance intensification may need to be immune-niche matched rather than tumor-cell matched alone. In other words, the next incremental gain after ASCT may come not simply from adding another anti-myeloma drug, but from disabling the specific suppressive networks induced by transplantation and maintenance itself.
CSF-1R targeting: what the broader oncology literature contributes
While CSF-1R inhibition is relatively new in myeloma, the concept is supported by broader oncology research. In solid tumors, early-phase studies of antibodies such as emactuzumab and small-molecule inhibitors such as pexidartinib demonstrated that CSF-1R blockade can deplete or repolarize macrophage populations and alter the tumor immune microenvironment. Clinical activity as monotherapy has often been modest outside selected macrophage-driven diseases, but the pharmacodynamic proof-of-mechanism has been clear: CSF-1R is druggable, and suppressive myeloid compartments can be therapeutically remodeled.
That broader experience is directly relevant to the Minnie study’s combination logic. If macrophage depletion alone produces limited tumor control, that does not invalidate the target; it may instead indicate that myeloid reprogramming is best deployed in combination with agents that expand or unleash effector lymphocytes. In this framework, lenalidomide becomes the immune activator and CSF-1R blockade the immune disinhibitor.
The mention of axatilimab adds practical urgency. Although developed in chronic graft-versus-host disease, axatilimab validates the clinical tractability of the CSF-1R axis in a transplant-related immune setting. Even if the exact pharmacology and disease context differ from myeloma maintenance, the regulatory precedent lowers the barrier to designing a post-ASCT biomarker-driven trial.
Potential positioning in the modern myeloma treatment landscape
The relevance of this strategy must be judged against current myeloma therapy, which is increasingly crowded with anti-CD38 antibodies, proteasome inhibitors, cereblon E3 ligase modulators, bispecific antibodies, and CAR T-cell therapy. Why should a maintenance strategy targeting macrophages still matter?
First, ASCT remains widely used even in the era of quadruplet induction. Second, relapse after ASCT still occurs across risk groups, especially when measurable residual disease persists. Third, post-ASCT maintenance is exactly where immune-modulating interventions may be most efficient: tumor burden is low, disease kinetics are slower, and adaptive immunity may still be restorable.
A CSF-1R-directed strategy could theoretically be most valuable in several scenarios: patients with persistent minimal residual disease after ASCT; patients with high-risk cytogenetics whose relapse risk remains high despite lenalidomide; patients with marrow immune signatures showing macrophage enrichment or high PD-L1/CD155 expression; and patients in whom T-cell exhaustion markers emerge early during maintenance. Importantly, the combination proposed by Minnie et al. does not compete directly with later-line cellular therapies; it may instead delay or reduce the need for them.
Methodological strengths of the Minnie et al. study
Several aspects of the study strengthen its credibility.
- Human-to-model linkage: The work starts from patient relapse-associated marrow findings and then tests causality in a preclinical ASCT model rather than relying on de novo animal observations alone.
- Mechanistic depth: Single-cell RNA sequencing and cell-cell communication analysis go beyond bulk immunophenotyping and generate a coherent circuit-level explanation for the observed synergy.
- Nonredundant combination design: The lack of substantial monotherapy benefit but clear combination efficacy supports a biologically meaningful interaction rather than simple dose stacking.
- Clinical immediacy: The target is therapeutically actionable with agents already in clinical development or practice.
Limitations and unanswered questions
Despite its importance, the study should not be overextended.
First, the efficacy data are preclinical. The central claim is therefore hypothesis-generating for human therapy, not yet practice changing. Second, marrow macrophages are heterogeneous, and depletion strategies can have unintended consequences, including impaired tissue repair, infection susceptibility, or disruption of beneficial antigen presentation. The identified CD64+CD169+CD163+ subset may not be fully recapitulated across all patient populations or treatment backbones.
Third, contemporary frontline myeloma care increasingly incorporates daratumumab and sometimes MRD-adapted approaches; the immune landscape after quadruplet induction plus ASCT may differ from that modeled experimentally. Fourth, biomarker development will be essential. It remains unclear whether simple flow cytometry for CSF-1R+ macrophages, immunohistochemistry, spatial transcriptomics, or composite immune signatures will best identify candidates for treatment.
Fifth, the optimal way to combine CSF-1R blockade with other post-ASCT therapies is unknown. If a patient receives lenalidomide plus an anti-CD38 antibody, does CSF-1R inhibition further enhance benefit, or does it increase toxicity without sufficient incremental efficacy? Finally, the study identifies PD-L1/PD-1 and CD94/NKG2A as relevant suppressive interactions, raising the possibility that CSF-1R inhibition may be one of several possible interventions. Whether macrophage depletion is superior to dual checkpoint modulation remains unknown.
Expert Commentary
The 2026 report by Minnie et al. is best viewed as a high-quality translational study that narrows a broad concept into a specific and testable post-ASCT maintenance hypothesis. The broader concept—that macrophages help myeloma evade immunity—has been recognized for years. What is new here is the timing, the cell-state resolution, and the therapeutic framing.
Timing matters because ASCT creates a temporary window in which disease burden is low but the immune ecosystem is unstable. This window is likely more manipulable than heavily pretreated relapsed disease. Cell-state resolution matters because not all macrophages are equivalent; the identified CSF-1R+PD-L1+CD155+ population links relapse to a concrete immunosuppressive program rather than a vague increase in “myeloid cells.” Therapeutic framing matters because the study does not argue for replacing lenalidomide maintenance. Instead, it explains why lenalidomide alone may be insufficient and proposes a rational adjunct that amplifies rather than duplicates its action.
Clinically, the next step should not be broad empiric use of CSF-1R blockade after ASCT. Rather, the field needs early-phase trials with deep correlative science. These should include serial marrow sampling, single-cell or high-parameter immune profiling, measurable residual disease assessment, and prospective biomarker stratification. End points should extend beyond safety and PFS to include proof that CSF-1R blockade depletes the target macrophage population, reduces inhibitory receptor expression on CD8 populations, and shifts the marrow toward a more permissive immune state.
There is also a policy and implementation angle. Because maintenance therapy is administered for prolonged periods, tolerability thresholds are high. Any added agent must not meaningfully compromise quality of life, hematopoietic recovery, or infection risk. This is particularly relevant in an older transplant-eligible population and in health systems already managing the cost burden of prolonged myeloma therapy.
From a strategic perspective, this work reinforces a broader shift in hematologic oncology: durable disease control increasingly depends on reshaping the host immune microenvironment, not just suppressing the malignant clone. In myeloma, this principle has already been validated indirectly by the success of anti-CD38 antibodies, T-cell redirection, and cellular therapies. The Minnie study extends that logic to the maintenance setting and to the myeloid compartment specifically.
Conclusion
Lenalidomide maintenance after ASCT remains a cornerstone of care for transplant-eligible multiple myeloma, but relapse continues to define the major unmet need. Minnie and colleagues provide persuasive evidence that one mechanism of post-ASCT failure may be the expansion of a CSF-1R+, PD-L1+, CD155+ suppressive macrophage subset that counteracts lenalidomide-induced cytotoxic lymphocyte activation. In preclinical models, CSF-1R inhibition alone was insufficient and lenalidomide alone was limited, but the combination produced synergistic disease control and survival benefit.
The study’s importance lies in its translational precision. It offers a biologically coherent explanation for incomplete maintenance efficacy, identifies a tractable target, and suggests a near-term clinical strategy supported by existing drug-development experience in the CSF-1R pathway. The path forward now requires biomarker-driven clinical trials, careful safety assessment, and integration with modern myeloma treatment backbones. If validated, CSF-1R blockade could become a novel immune-niche-directed enhancement of standard post-ASCT maintenance rather than a competing paradigm.
References
- Minnie SA, Ho K, Boiko JR, Adams RC, Ensbey KS, Nemychenkov NS, Legg SRW, Schmidt CR, Comstock ML, Lyons JM, Sekiguchi T, Koyama M, Spencer A, Green DJ, Hill GR. CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation. Blood. 2026;147(23):2786-2792. PMID: 41770790.
- McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-1781. PMID: 22571201.
- Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-1791. PMID: 22927360.
- Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, et al. Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide versus placebo maintenance after single autologous stem cell transplant for multiple myeloma. Lancet Haematol. 2017;4(9):e431-e442. PMID: 28826616.
- McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279-3289. PMID: 28742454.
- Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846-859. PMID: 24898549.
- Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, D’Angelo SP, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumour of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16(8):949-956. PMID: 26179247.
- Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373(5):428-437. PMID: 26222558.
- Andersen MN, Andersen NF, Rødgaard-Hansen S, Hokland M, Abildgaard N, Møller HJ. The novel biomarker of alternative macrophage activation, soluble CD163, is elevated in multiple myeloma and associated with more advanced disease. Eur J Haematol. 2014;93(1):41-47. PMID: 24628756.
- Sponaas AM, Moen SH, Liabakk NB, Feyzi E, Holien T, Kvam S, et al. The role of interleukin-1 in the pathogenesis of multiple myeloma: implications for tumor-associated macrophages and immunotherapy. Oncoimmunology. 2015;4(8):e1043177. PMID: 26451328.